Keythera Biopharmaceuticals Will Present the Research Findings on KF-0210 at AACR 2023
2023-04-04
Keythera Biopharmaceuticals will present the preclinical research results of their anti-tumor small molecule compound, KF-0210, at AACR 2023, which will be held from April 14 to 19, 2023, in Orlando, Florida, USA.
Title: Discovery of an EP4 receptor antagonist KF-0210 for the treatment of cancers
Session Title: Modifiers of the Tumor Microenvironment
Published Abstract Number: 2330
Session Category: Clinical Research Excluding Trials Session
Date and Time: Monday, April 17, 2023, 9:00 AM - 12:30 PM
Location: Poster Section 45
PGE2 primarily regulates the tumor microenvironment and tumor growth through the EP4 receptor in tumor tissues. Inhibiting the EP4 receptor increases the infiltration of cytotoxic immune cells in tumor tissues, thereby enhancing the tumor's response to PD-1/PD-L1 antibody therapy. This study reports the potent and highly selective EP4 receptor antagonist, KF-0210, developed by Keythera Biopharmaceuticals for anti-tumor treatment. In binding experiments with the EP4 receptor, KF-0210 demonstrated a strong binding affinity to the EP4 receptor, more than 500 times higher than other prostaglandin receptors such as EP1, EP2, EP3, IP, DP1, and FP. KF-0210 also exhibited a strong inhibitory effect on cAMP generation in cells induced by PGE2. In pharmacokinetic studies in rats and mice, oral administration of KF-0210 resulted in high plasma exposure. In a CT26 colorectal cancer mouse model, KF-0210 inhibited tumor growth by increasing the infiltration of cytotoxic immune cells in tumor tissues. In combination therapy studies, the inhibitory effect on tumor growth of the combination of KF-0210 and PD-1/PD-L1 antibodies was superior to monotherapy (P<0.001). No significant safety issues were observed in in vivo toxicity and safety studies. Currently, the clinical development of KF-0210 as a monotherapy or in combination with PD-1/PD-L1 antibodies for the treatment of solid tumors is ongoing.
According to the disclosure, the American Association for Cancer Research (AACR) was established in 1907 and is the oldest and largest scientific organization in the world. AACR Annual Meetings cover the latest discoveries in cancer research and serve as a global focal point for oncology research, bringing together cutting-edge research in the field of oncology.
About Keythera Biopharmaceuticals
Keythera Biopharmaceuticals is a clinical-stage biotechnology company specializing in the clinical development of small molecule new drugs for oncology and autoimmune diseases. The company's founders and management team have extensive experience in preclinical and clinical development, as well as world-class innovative capabilities. Through a comprehensive strategy centered around its product pipeline and supported by its technological platform, the company has effectively accelerated new drug development, reduced the risks associated with new drug development, and achieved differentiation in its product pipeline. The company currently has six product pipelines covering the fields of oncology and autoimmune diseases. Since its establishment, the company has received multiple honors and awards, including being recognized as a leading company in Suzhou Industrial Park and Gu Su, winning the first prize in the Start-up Group of the 10th Innovation and Entrepreneurship Competition in 2021, and being selected as a unicorn cultivation enterprise in Suzhou in 2022.
Back to List
0512-63020039
info@keytherapharma.com
Unit B2-508, Bio-Bay, 218 Xinghu Street, SIP, Suzhou, Jiangsu, China
苏公网安备32059002005508号
